Corey M. Casey

I'll research this attorney before drafting.

Let me clarify the case posture and gather background details.

Let me verify the case posture, outcomes, and PTAB involvement.

Corey M. Casey — Patent Litigation Practice Summary

Focus areas. Casey is a life-sciences patent lawyer, not a generalist IP litigator. His practice centers on Hatch-Waxman/ANDA patent litigation and biologics work, with technical experience in pharmaceutical, biotechnology, and chemical technologies. His Polsinelli/third-party practice descriptions also list patent preparation and prosecution, patent opinions, IP estate assessment and due diligence, licensing, and biosimilar product assessment. He is not a Wi-Fi/standards, software, or mechanical practice. He is a registered pharmacist (Pharm.D.) and a registered patent attorney, and IAM Patent 1000 has listed him as "Recommended – Prosecution" for Missouri.

Side preference. The authoritative tracker shows 2 plaintiff-side and 0 defendant-side appearances, but both entries are the same matter (Padagis US LLC v. Neurelis, Inc.) recorded twice, and he appears as back-up counsel in each. Substantively that matter places him on the generic/ANDA-filer side: Padagis is the petitioner against Neurelis's patents at the PTAB, and Padagis is the ANDA defendant in the mirror-image district court case (Neurelis, Inc. v. Padagis LLC, D. Del.). His own published practice description states he represents both brand and generic companies, so the tracked plaintiff-side tally reflects a single generics-side engagement rather than a consistent NPE/PAE-style plaintiff practice.

Firm context. He is a Shareholder at Polsinelli PC, based in the firm's Kansas City office, and a member of the firm's national Hatch-Waxman Litigation Practice and Science and Technology Group. Sources show him at Polsinelli (formerly Polsinelli Shughart) since at least 2009; no prior firm relevant to his patent litigation career is documented.

Notable matters, PTAB, and credentials. His tracked engagement is the Padagis/Neurelis dispute over Neurelis's VALTOCO (diazepam nasal spray) patents — U.S. Patent Nos. 8,895,546, 11,241,414, and 11,793,786 — consolidated as PTAB proceedings IPR2025-00464, -00465, and -00466, where he is back-up counsel to lead counsel James P. Murphy for petitioner Padagis. That matter produced an informative Director-level ruling: Acting Director Coke Morgan Stewart's July 2025 decision declining discretionary denial under Fintiv (citing an earlier IPR on related Neurelis patent 9,763,876 that ended in an unpatentability finding affirmed by the Federal Circuit), designated informative by Director John Squires on January 9, 2026. The proceedings have since moved past institution toward a projected final written decision around September 17, 2026, with certificate-of-correction and discovery disputes litigated. Beyond this matter, his practice descriptions indicate service as counsel in multiple IPRs in the pharmaceutical and medical device spaces, though those specific proceedings are not reflected in the tracked data. Education/bar: Pharm.D., University of Missouri–Kansas City (2006); J.D., University of Missouri–Kansas City (2009); admitted in Missouri (2009) and Kansas (2010); USPTO Registration No. 66,950. Separately, a Law360 attorney profile lists an appearance for him in Novartis Pharmaceuticals Corp. v. Becerra (D.D.C., filed July 2024); I could not verify his role in that case, and it does not appear in the tracked case list.